IL143092A0 - Stabilization of macrolides - Google Patents

Stabilization of macrolides

Info

Publication number
IL143092A0
IL143092A0 IL14309299A IL14309299A IL143092A0 IL 143092 A0 IL143092 A0 IL 143092A0 IL 14309299 A IL14309299 A IL 14309299A IL 14309299 A IL14309299 A IL 14309299A IL 143092 A0 IL143092 A0 IL 143092A0
Authority
IL
Israel
Prior art keywords
macrolides
stabilization
Prior art date
Application number
IL14309299A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143092(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL143092A0 publication Critical patent/IL143092A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL14309299A 1998-12-07 1999-12-06 Stabilization of macrolides IL143092A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Publications (1)

Publication Number Publication Date
IL143092A0 true IL143092A0 (en) 2002-04-21

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14309299A IL143092A0 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Country Status (38)

Country Link
US (5) US6605613B2 (cs)
EP (4) EP1743657A3 (cs)
JP (3) JP3805625B2 (cs)
KR (2) KR100695834B1 (cs)
CN (2) CN1876657B (cs)
AR (3) AR026102A1 (cs)
AT (1) ATE365051T1 (cs)
AU (1) AU759219B2 (cs)
BE (1) BE1012869A3 (cs)
BR (1) BR9915986A (cs)
CA (3) CA2651609A1 (cs)
CO (1) CO4980847A1 (cs)
CY (1) CY1106870T1 (cs)
CZ (2) CZ302210B6 (cs)
DE (1) DE69936352T3 (cs)
DK (1) DK1137439T4 (cs)
ES (1) ES2288033T5 (cs)
FR (1) FR2786771B1 (cs)
GB (2) GB9826882D0 (cs)
HK (1) HK1038889B (cs)
HU (2) HU230174B1 (cs)
ID (1) ID29250A (cs)
IL (1) IL143092A0 (cs)
IT (1) IT1319701B1 (cs)
MY (2) MY120594A (cs)
NO (2) NO332698B1 (cs)
NZ (2) NZ511936A (cs)
PE (1) PE20001333A1 (cs)
PL (2) PL196627B1 (cs)
PT (1) PT1137439E (cs)
RU (1) RU2243769C2 (cs)
SG (1) SG151072A1 (cs)
SI (1) SI1137439T2 (cs)
SK (2) SK286688B6 (cs)
TR (2) TR200101416T2 (cs)
TW (2) TWI248938B (cs)
WO (1) WO2000033878A2 (cs)
ZA (1) ZA200104360B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
HRP20040765A2 (en) 2002-02-13 2005-02-28 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
ES2300622T3 (es) 2002-07-30 2008-06-16 Wyeth Formulaciones parenterales que contienen un hidroxiester de rapamicina.
KR20050114262A (ko) * 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ES2297481T3 (es) 2003-07-24 2008-05-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Metodo para purificar macrolidos.
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CA2548596A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd. Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
KR20070083839A (ko) * 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
EP1957964A2 (en) * 2005-12-07 2008-08-20 Wyeth Pharmaceuticals Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP1962819A1 (en) * 2005-12-20 2008-09-03 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
CA2797501A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
JP5985474B2 (ja) * 2010-08-04 2016-09-06 メリル ライフ サイエンシズ ピーブィティ．エルティディ 抗増殖特性を有する新規４２−ｏ−（ヘテロアルコキシアルキル）ラパマイシン化合物の調製プロセス
ES2753529T3 (es) 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (cs) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
WO2017038612A1 (ja) * 2015-08-28 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
EP3466424A1 (en) 2016-05-27 2019-04-10 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprizing rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
AU2021242202B2 (en) * 2020-03-27 2024-01-11 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) * 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE69333995T2 (de) 1992-10-13 2006-10-19 Wyeth Carbamate von Rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
PL184731B1 (pl) * 1995-06-09 2002-12-31 Novartis Ag Pochodne rapamycyny, zastosowanie pochodnych rapamycyny i kompozycja farmaceutyczna
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
NZ333657A (en) * 1996-07-30 2000-05-26 Novartis Ag A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
EP0975330A1 (en) 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
EP1137439B1 (en) 2007-06-20
US20050107418A1 (en) 2005-05-19
US20090270441A1 (en) 2009-10-29
AU1657300A (en) 2000-06-26
CN1374872A (zh) 2002-10-16
ES2288033T5 (es) 2012-04-10
AR026102A1 (es) 2003-01-29
RU2243769C2 (ru) 2005-01-10
JP5165199B2 (ja) 2013-03-21
AU759219B2 (en) 2003-04-10
SI1137439T1 (sl) 2008-06-30
JP2005200429A (ja) 2005-07-28
TR200101416T2 (tr) 2002-01-21
CZ303006B6 (cs) 2012-02-22
NZ511936A (en) 2003-10-31
CA2732620C (en) 2013-08-06
DE69936352T2 (de) 2008-02-14
KR20010101128A (ko) 2001-11-14
US6852729B2 (en) 2005-02-08
AR054444A2 (es) 2007-06-27
CA2651609A1 (en) 2000-06-15
EP1743657A2 (en) 2007-01-17
ITMI992520A0 (it) 1999-12-02
IT1319701B1 (it) 2003-10-27
NO332698B1 (no) 2012-12-10
SK7662001A3 (en) 2001-12-03
MY127579A (en) 2006-12-29
HUP0104489A2 (hu) 2002-03-28
JP2002531527A (ja) 2002-09-24
FR2786771A1 (fr) 2000-06-09
HK1038889B (en) 2008-01-25
CA2351580C (en) 2012-03-20
EP2279751A3 (en) 2011-02-16
TR200201428T2 (tr) 2002-12-23
US20030191148A1 (en) 2003-10-09
BR9915986A (pt) 2001-09-04
PL196627B1 (pl) 2008-01-31
US7297703B2 (en) 2007-11-20
CN1876657B (zh) 2013-01-09
DE69936352T3 (de) 2012-05-03
CO4980847A1 (es) 2000-11-27
EP1137439B2 (en) 2011-11-23
TWI270550B (en) 2007-01-11
PE20001333A1 (es) 2000-12-12
ES2288033T3 (es) 2007-12-16
PL348333A1 (en) 2002-05-20
SI1137439T2 (sl) 2012-05-31
TW200540179A (en) 2005-12-16
NO20012424L (no) 2001-05-16
SK286688B6 (sk) 2009-03-05
EP2269651A3 (en) 2011-03-09
CZ302210B6 (cs) 2010-12-22
CN1876657A (zh) 2006-12-13
ZA200104360B (en) 2002-01-16
KR100695834B1 (ko) 2007-03-19
PT1137439E (pt) 2007-09-25
SK287325B6 (sk) 2010-07-07
NZ527781A (en) 2004-11-26
AR048073A2 (es) 2006-03-29
US7741338B2 (en) 2010-06-22
US20080161334A1 (en) 2008-07-03
FR2786771B1 (fr) 2002-12-27
EP2269651A2 (en) 2011-01-05
DK1137439T4 (da) 2012-03-19
MY120594A (en) 2005-11-30
WO2000033878A3 (en) 2000-11-02
GB9904934D0 (en) 1999-04-28
TWI248938B (en) 2006-02-11
ID29250A (id) 2001-08-16
BE1012869A3 (fr) 2001-04-03
CA2732620A1 (en) 2000-06-15
CZ20012001A3 (cs) 2001-09-12
HU230174B1 (hu) 2015-09-28
NO20121113L (no) 2001-05-16
CN1261163C (zh) 2006-06-28
ITMI992520A1 (it) 2001-06-02
US7572804B2 (en) 2009-08-11
DE69936352D1 (de) 2007-08-02
GB9826882D0 (en) 1999-01-27
EP2279751A2 (en) 2011-02-02
HUP0104489A3 (en) 2004-05-28
US20020032213A1 (en) 2002-03-14
CA2351580A1 (en) 2000-06-15
EP1743657A3 (en) 2007-03-28
HK1038889A1 (en) 2002-04-04
HU228939B1 (en) 2013-07-29
WO2000033878A2 (en) 2000-06-15
US6605613B2 (en) 2003-08-12
ATE365051T1 (de) 2007-07-15
JP3805625B2 (ja) 2006-08-02
EP1137439A2 (en) 2001-10-04
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
NO334612B1 (no) 2014-04-22
JP2006111637A (ja) 2006-04-27
PL208854B1 (pl) 2011-06-30
NO20012424D0 (no) 2001-05-16
SG151072A1 (en) 2009-06-29
JP5043308B2 (ja) 2012-10-10
KR20060096477A (ko) 2006-09-11

Similar Documents

Publication Publication Date Title
IL143092A0 (en) Stabilization of macrolides
IL137024A0 (en) Novel macrolides
PL341647A1 (en) Novel derivatives of erythromycin
PL346544A1 (en) Crystalline forms of eto2
PL340290A1 (en) 2-halogeno-6-0-substituted derivatives of ketolide
TW364383U (en) Improvement on structure of wrist-ball
PL342733A1 (en) Biocement of improved properties
SG83724A1 (en) Novel polyene macrolide compounds and uses
TW399818U (en) Structure of connector
HUP9902855A3 (en) Preparation of sterol- and stanol-esters
AU2003200370A1 (en) Stabilization of macrolides
TW371522U (en) Card-rejection mechanism of connector
AU3898299A (en) Thermal treatment wall
TW398188U (en) Improved structure of de-hooker
TW354479U (en) Improvement of earpick
GB9914540D0 (en) Colonicure or RKH colone
TW355988U (en) Improved structure for inserting-hook of curtain
TW428810U (en) Improved structure of plug
TW433622U (en) Improved structure of plug
GB9820641D0 (en) Stabilisation of peroxidases
GB9818178D0 (en) Curtain walls
TW380759U (en) Structure of extended plug
TW364693U (en) Inside structure of plug
TW392981U (en) Improvement of connector
GB9826768D0 (en) Improvements relating to stabilising devices

Legal Events

Date Code Title Description
EXTN Extension order renewed
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired